Real-World Impact of Pneumococcal Conjugate Vaccines on Vaccine Serotypes and Potential Cross-Reacting Non-Vaccine Serotypes
The inclusion of VT 19A in PCV13, but not in PCV10, may account for the significant increase in VRT 19A cases in PCV10 countries. The slight change in VRT 6C cases in PCV13 countries compared to the significant rise in PCV10 countries suggests that PCV13 provides cross-protection for serotype 6C through serotype 6A. Cross-protection could not be determined for other VRTs, as their cases increased or remained unchanged or had insufficient data for evaluation.
Authors
- Johnna Perdrizet (ORCID: https://orcid.org/0000-0002-4260-7607)
- Lindsay R. Grant (ORCID: https://orcid.org/0000-0002-4538-6424)
- Gabriel Mircus (ORCID: https://orcid.org/0009-0009-3112-363X)
- Kevin Apodaca (ORCID: https://orcid.org/0000-0003-2222-7954)
- Bradford D. Gessner (ORCID: https://orcid.org/0000-0002-6216-7194)
- Derek Daigle (ORCID: https://orcid.org/0009-0007-4350-6967)
Institutions
- Pfizer (United States) (US)
Publication Details
- Journal
- Vaccines
- Published
- 2025-06-17
- DOI
- https://doi.org/10.3390/vaccines13060651
- Citations
- 1
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Pfizer